v2.4.0.8

Collaboration Revenue - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended		12 Months Ended				0 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended			0 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended	0 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended			3 Months Ended	9 Months Ended		12 Months Ended		3 Months Ended	9 Months Ended	12 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended		0 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended	0 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended		3 Months Ended	9 Months Ended	12 Months Ended	1 Months Ended	0 Months Ended	1 Months Ended		1 Months Ended	3 Months Ended	9 Months Ended	1 Months Ended	3 Months Ended	9 Months Ended	1 Months Ended		3 Months Ended	9 Months Ended	0 Months Ended		0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	1 Months Ended					3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2013 Upfront and Milestone Payments [Member]	Dec. 31, 2012 Upfront and Milestone Payments [Member]	Jan. 06, 2011 Ziopharm Oncology ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Oct. 24, 2012 Ziopharm Oncology ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Milestone One [Member]	Sep. 30, 2013 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2012 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2012 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Dec. 31, 2012 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Dec. 31, 2011 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Jan. 06, 2011 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Oct. 24, 2012 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Milestone One [Member]	Sep. 30, 2013 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Milestone One [Member]	Sep. 30, 2013 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Milestone One [Member]	Dec. 31, 2012 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Milestone One [Member]	Jan. 06, 2011 Ziopharm Oncology ECC [Member]	Jan. 06, 2011 Ziopharm Oncology ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Oct. 24, 2012 Ziopharm Oncology ECC [Member] Upfront and Milestone Payments [Member] Milestone One [Member]	Sep. 30, 2013 Ziopharm Oncology ECC [Member] Research and Development Services [Member]	Sep. 30, 2012 Ziopharm Oncology ECC [Member] Research and Development Services [Member]	Sep. 30, 2013 Ziopharm Oncology ECC [Member] Research and Development Services [Member]	Sep. 30, 2012 Ziopharm Oncology ECC [Member] Research and Development Services [Member]	Dec. 31, 2012 Ziopharm Oncology ECC [Member] Research and Development Services [Member]	Dec. 31, 2011 Ziopharm Oncology ECC [Member] Research and Development Services [Member]	Mar. 21, 2012 Ziopharm Oncology ECC [Member] Research and Development Services [Member]	Sep. 30, 2012 Synthetic Biologics Field One ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Synthetic Biologics Field One ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2012 Synthetic Biologics Field One ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Dec. 31, 2012 Synthetic Biologics Field One ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Dec. 31, 2011 Synthetic Biologics Field One ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Synthetic Biologics Field Two ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Synthetic Biologics Field Two ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Dec. 31, 2012 Synthetic Biologics Field Two ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Synthetic Biologics [Member] Research and Development Services [Member]	Sep. 30, 2012 Synthetic Biologics [Member] Research and Development Services [Member]	Sep. 30, 2013 Synthetic Biologics [Member] Research and Development Services [Member]	Sep. 30, 2012 Synthetic Biologics [Member] Research and Development Services [Member]	Dec. 31, 2012 Synthetic Biologics [Member] Research and Development Services [Member]	Dec. 17, 2012 Synthetic Biologics [Member] Research and Development Services [Member]	Nov. 28, 2011 Elanco ECC [Member]	Nov. 28, 2011 Elanco ECC [Member] Maximum [Member]	Sep. 30, 2013 Elanco ECC [Member] Research and Development Services [Member]	Sep. 30, 2012 Elanco ECC [Member] Research and Development Services [Member]	Sep. 30, 2013 Elanco ECC [Member] Research and Development Services [Member]	Sep. 30, 2012 Elanco ECC [Member] Research and Development Services [Member]	Dec. 31, 2012 Elanco ECC [Member] Research and Development Services [Member]	Sep. 30, 2013 Oragenics ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2012 Oragenics ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Oragenics ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2012 Oragenics ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Dec. 31, 2012 Oragenics ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Jun. 05, 2012 Oragenics ECC [Member]	Jun. 05, 2012 Oragenics ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Oragenics ECC [Member] Research and Development Services [Member]	Sep. 30, 2012 Oragenics ECC [Member] Research and Development Services [Member]	Sep. 30, 2013 Oragenics ECC [Member] Research and Development Services [Member]	Sep. 30, 2012 Oragenics ECC [Member] Research and Development Services [Member]	Dec. 31, 2012 Oragenics ECC [Member] Research and Development Services [Member]	Sep. 30, 2013 Fibrocell Science ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Fibrocell Science ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Dec. 31, 2012 Fibrocell Science ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Jun. 28, 2013 Fibrocell Science ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Supplemental Upfront [Member]	Sep. 30, 2013 Fibrocell Science ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Supplemental Upfront [Member]	Sep. 30, 2013 Fibrocell Science ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Supplemental Upfront [Member]	Oct. 05, 2012 Fibrocell Science ECC [Member]	Oct. 05, 2012 Fibrocell Science ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Fibrocell Science ECC [Member] Research and Development Services [Member]	Sep. 30, 2013 Fibrocell Science ECC [Member] Research and Development Services [Member]	Dec. 31, 2012 Fibrocell Science ECC [Member] Research and Development Services [Member]	Nov. 18, 2011 Synthetic Biologics Field One ECC [Member]	Nov. 18, 2011 Synthetic Biologics Field One ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Mar. 31, 2013 AmpliPhi ECC [Member]	Mar. 31, 2013 AmpliPhi ECC [Member] Maximum [Member]	Mar. 31, 2013 AmpliPhi ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 AmpliPhi ECC [Member] Research and Development Services [Member]	Sep. 30, 2013 AmpliPhi ECC [Member] Research and Development Services [Member]	Mar. 31, 2013 AmpliPhi ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 AmpliPhi ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 AmpliPhi ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Mar. 31, 2013 Genopaver ECC [Member]	Mar. 31, 2013 Genopaver ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Genopaver ECC [Member] Research and Development Services [Member]	Sep. 30, 2013 Genopaver ECC [Member] Research and Development Services [Member]	Apr. 27, 2013 Soligenix ECC [Member]	Apr. 27, 2013 Soligenix ECC [Member] Maximum [Member]	Apr. 27, 2013 Soligenix ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Soligenix ECC [Member] Research and Development Services [Member]	Sep. 30, 2013 Soligenix ECC [Member] Research and Development Services [Member]	Feb. 14, 2013 AquaBounty ECC [Member]	Aug. 06, 2012 Synthetic Biologics Field Two ECC [Member]	Oct. 05, 2012 Synthetic Biologics Field Two ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Oragenics Second ECC [Member]	Sep. 30, 2013 Oragenics Second ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Oragenics Second Ecc Unit Of Accounting One [Member]	Sep. 30, 2013 Genopaver ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Genopaver ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Soligenix ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]	Sep. 30, 2013 Soligenix ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]
Collaboration Agreements [Line Items]
Collaborative arrangement consideration received, shares																							3,636,926	3,636,926																																			4,392,425									1,243,781				1,317,520					3,123,558			24,000,000												1,034,483					3,552,210		1,348,000
Collaborative arrangement consideration received, value										$ 1,171								$ 17,159					$ 17,457	$ 18,330																																			$ 6,588													$ 7,576					$ 1,687			$ 2,400			$ 2,400				$ 3,000					$ 1,331					$ 7,815		$ 3,503
Percent of shares outstanding at the date of achievement of future milestone																						7.495%																																				1.00%																		9.995%
Royalty rate as a percentage of net profit																						50.00%																																				25.00%																		50.00%
Required notice period for voluntary termination of collaborative agreement																						90 days																								90 days												90 days													90 days					90 days		90 days								90 days				90 days						90 days		90 days
Period when agreement cannot be voluntarily terminated																						2 years																																				18 months																		18 months																				18 months
Collaboration revenue	6,028	2,904	16,566	7,163	13,706	5,118			1,115		314	314	942	943	1,257	1,257		2,420	330	990	220				2,122	2,137	5,843	5,095	6,333	2,724		33	1,535	97	130	22	163	489	163	176	71	865	194	327				90	51	289	485	587	138	137	412	182	320			344	137	1,057	137	516	158	474	158		169	169			1,383	2,428	61						128	162		54	109			315	528				13	13							68	136	30	50
Deferred revenue	67,392		67,392		58,636		65,846	51,359			12,886		12,886		13,828		16,342	14,739	13,529	13,529	14,519								4,862		10,000				1,535		7,163	7,163	7,652	1,502		1,502		2,367	2,500								5,857		5,857		6,268								6,944	6,944	7,418	7,612	7,443	7,443														2,291	2,291															5,459	2,864	2,864	1,281	1,281
Deferred revenue current	7,398		7,398		9,963	1,402									1,257						1,320														130				651																		549										631
Collaboration revenue for research and development services applied against the prepayment																									1,141	1,893	4,862	3,900	5,138															133
Related party receivables	4,538		4,538		531	272																			981		981			215																														220		220		270									1,041	1,041	61						67	67						241	241				13	13
Consideration to be received upon achievement of future milestone 1																																																																																																2,000		2,000
Consideration to be received upon achievement of future milestone 2																																																																																																3,000		5,000
Field expansion fee																																																																																																2,000
Aggregate consideration to be received upon achievement of future milestones per product																																															2,250																																7,500												7,000
Required notice period for voluntary termination of collaboration agreement if services in progress																																														180 days
Trade receivables	195		195		141	20																																										91		91		102
Percentage of shares outstanding at the date of achievement of future milestone 2																																																										1.50%
Percentage of shares outstanding at the date of achievement of future milestone 3																																																										2.00%
Percentage of shares outstanding at the date of achievement of future milestone 4																																																										2.50%
Percentage of shares outstanding at the date of achievement of future milestone 5																																																										3.00%
Number of reverse stock split																																																																								1-for-25 reverse stock split
Royalty rate as a percentage of net sales, tier 1																																																																							7.00%																											10.00%
Royalty rate as a percentage of net sales, tier 2																																																																							14.00%
Royalty rate of savings from improvement																																																																							33.00%
Level of net sales at which royalty rate changes to tier 2																																																																							25,000
Maturity date of promissory note																																																																																																			December 31, 2013
Collaborative arrangement consideration received, value of convertible promissory note																																																																																																			1,956
Consideration to be received upon achievement of future milestone 3																																																																																																		$ 10,000
Royalty rate as a percentage of gross profit																																																																																															16.66%

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5



Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name:	us-gaap_AccountsReceivableNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765



Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864



Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5



Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682



Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765



Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 2

-Article 4

+ Details

Name:	us-gaap_DueFromRelatedPartiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Description of the terms and manner of settlement of the related party transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name:	us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The period at the beginning of the collaborative agreement during which the collaborative partner cannot voluntarily terminate the agreement.

+ References

No definition available.

+ Details

Name:	xon_CollaborationAgreementPeriodWhenVoluntaryTerminationIsNotAllowed
Namespace Prefix:	xon_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	xon_CollaborationAgreementsLineItems
Namespace Prefix:	xon_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Notice period required for voluntary termination by collaborative partner of collaborative agreement.

+ References

No definition available.

+ Details

Name:	xon_CollaborationAgreementTerminationNoticePeriod
Namespace Prefix:	xon_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaboration agreement termination notice period if services in progress.

+ References

No definition available.

+ Details

Name:	xon_CollaborationAgreementTerminationNoticePeriodIfServicesInProgress
Namespace Prefix:	xon_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Revenue recognized from contractual agreements with collaborative partners where the entity receives payments for research and development and/or manufacturing services, as provided for in the agreements, and recognizes deferred revenues from contractual upfront and milestone payments from the partners.

+ References

No definition available.

+ Details

Name:	xon_CollaborationRevenues
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaborative agreement aggregate future milestone consideration per product.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeAgreementAggregateFutureMilestoneConsiderationPerProduct
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Collaborative agreement field expansion fee.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeAgreementFieldExpansionFee
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Percent of shares outstanding at the date of achievement of a future milestone, representing maximum range of shares to which the entity is entitled to receive upon achievement of said milestone.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingShares
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Collaborative arrangement additional consideration receivable as percentage of outstanding shares five.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFive
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Collaborative arrangement additional consideration receivable as percentage of outstanding shares four.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFour
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Collaborative arrangement additional consideration receivable as percentage of outstanding shares three.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesThree
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Collaborative arrangement additional consideration receivable as percentage of outstanding shares two.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesTwo
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Collaborative arrangement consideration received shares.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementConsiderationReceivedShares
Namespace Prefix:	xon_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative arrangement consideration received value.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementConsiderationReceivedValue
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaborative Arrangement Consideration Received Value of Convertible Promissory Note

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaborative arrangement net sales at which royalty rate changes to tier two.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Collaborative arrangement royalties as percentage of net sales tier one.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative arrangement royalties as percentage of net sales tier two.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative arrangement royalty rate as percentage of gross profit.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementRoyaltyRateAsPercentageOfGrossProfit
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Rate of royalty payments due to entity under terms of collaborative arrangement, represented as a percentage of net profit.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementRoyaltyRateAsPercentageOfNetProfit
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative arrangement royalty rate as percentage of savings from improvement.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementRoyaltyRateAsPercentageOfSavingsFromImprovement
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Future milestone payment one.

+ References

No definition available.

+ Details

Name:	xon_FutureMilestonePaymentOne
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Future Milestone Payment Three

+ References

No definition available.

+ Details

Name:	xon_FutureMilestonePaymentThree
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Future milestone payment two.

+ References

No definition available.

+ Details

Name:	xon_FutureMilestonePaymentTwo
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Revenues applied towards prepayment research and development services.

+ References

No definition available.

+ Details

Name:	xon_RevenuesAppliedTowardsPrepaymentResearchAndDevelopmentServices
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Reverse stock split ratio on common stock.

+ References

No definition available.

+ Details

Name:	xon_ReverseStockSplitRatioOnCommonStock
Namespace Prefix:	xon_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	instant